glp-1 moa Frontiers GLP-1 and Anesthesia: Considerations and

Fu SC, Cheuk YC, Chiu WY, Yung SH, Rolf CG, Chan KM

Try out our Product

Regulating the profibrogenic cytokine TGF-, which is found to be elevated in fibrotic Autoimmune diseases such as systemic sclerosis

Sikiric et al., 2018), along with the evidence that pentadecapeptide BPC 157 may prevent and/or attenuate or eliminate, thus, counteract both developing and already formed both arterial thrombosis (Hrelec et al., 2009

Meanwhile, evidence is mounting of the wider therapeutic benefits of GLP-1 drugs, with clinical trials ongoing for metabolic liver disease, cardiovascular diseases, chronic kidney disease, and neurological disorders, among others